Nanobiotechnology-based drug delivery to the central nervous system.
Open accessAbstract
BACKGROUND: Drug delivery across the blood-brain barrier (BBB) is a major limitation in the treatment of central nervous system (CNS) disorders. Several approaches are being investigated to improve drug delivery across the BBB. OBJECTIVE/METHODS: This review deals with the role of nanobiotechnology in CNS drug delivery. The small size of the nanoparticles enables them to penetrate the BBB and facilitate the delivery of drugs across the barrier. Several mechanisms are involved in this process and various strategies are used based on different types of nanomaterial and combinations with therapeutic agents. Examples are given of the use of liposomes and polymeric nanoparticles. RESULTS: Nanoparticles can be used as nonviral vectors for CNS gene therapy. Although the use of nanotechnology is expected to reduce the need for invasive procedures for delivery of therapeutics to the CNS, some devices such as implanted catheters and reservoirs will still be needed. Nanomaterials can improve the safety and efficacy of such devices. Nano-engineered probes can deliver drugs at the cellular level using nanofluidic channels. There is some concern about the safety of nanoparticle entry in the brain and this needs to be resolved before human use. CONCLUSION: Although there is no approved nanotechnology-based CNS drug as yet that incorporates nanobiotechnology, the future for such developments is promising.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Carbon nanotubes as intracellular protein transporters: generality and biological functionality.
Kam, N. W., & Dai, H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja050062v · Cited by 985 · cited 1× · see citing works
“• Carbon nanotubes represent a new class of molecular transporters potentially useful for future in vitro and in vivo protein delivery applications [”
BackgroundApolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 1× · see citing works
“These carriers can penetrate the BBB and deliver drugs of various structures, including peptides, hydrophilic compounds and lipophilic compounds that are otherwise eliminated from the brain by P-glycoprotein. When a suspension of polysorbate-coated PBCA nanoparticles is introduced into blood, apolipoproteins of the bl…”
BackgroundNano-C60 cytotoxicity is due to lipid peroxidation
Sayes, C. M., Gobin, A. M., Ausman, K. D., Mendez, J. S., West, J. L., & Colvin, V. L. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.027 · Cited by 687 · see citing works
Bharali, D. J., Klejbor, I., Stachowiak, E. K., Dutta, P., Roy, I., Kaur, N., Bergey, E. J., Prasad, P. N., & Stachowiak, M. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504926102 · Cited by 622 · cited 1× · see citing works
“Antibody-conjugated liposomes or immunoliposomes are nanoparticulate drug carriers that can be used to direct encapsulated drug molecules to diseased tissues or organs. Role of Nanobiotechnology in Gene Therapy of CNS DisordersConsiderable developments are taking place in gene therapy, which is a sophisticated way of…”
BackgroundKreuter, J., Ramge, P., Petrov, V. E., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R. N., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469 · cited 1× · see citing works
“In vivo studies using the antinociceptive opioid peptide dalargin showed that both empty PBCA nanoparticles and polysorbate 80 did not allow dalargin to enter the brain in quantities sufficient to cause antinociception. Only dalargin preadsorbed to PBCA nanoparticles was able to induce an antinociceptive effect in the…”
BackgroundMichaelis, K., Hoffmann, M. M., Dreis, S., Herbert, E., Alyautdin, R. N., Michaelis, M., Kreuter, J., & Langer, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.097139 · Cited by 346 · cited 1× · see citing works
“The fact that dalargin has to be preadsorbed onto nanoparticles before it is effective in inducing antinociception suggests specific mechanisms of delivery to the CNS rather than a simple disruption of the BBB allowing a diffusional drug entry. Apolipoprotein E attached to the surface of nanoparticles facilitates the…”
BackgroundDecreased functions of astrocytes on carbon nanofiber materials
McKenzie, J. L., Waid, M. C., Shi, R., & Webster, T. J. (2003) · Biomaterials · doi:10.1016/j.biomaterials.2003.08.006 · Cited by 235 · cited 1× · see citing works
“Intraventricular and intracerebral stereotaxic injections of stable aqueous suspension of these nanoparticles, complexed with plasmid DNA encoding for enhanced green fluorescent protein, were made into the mouse brain. Targeted dopamine neurons, which degenerate in Parkinson’s disease, took up and expressed a fluoresc…”
BackgroundPeptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier
Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M. A., & Forni, F. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.013 · Cited by 208 · cited 1× · see citing works
“Conjugates between a biodegradable copolymer, poly( D , L -lactide-co-glycolide), and five short peptides have been synthesized by means of an amidic linkage to create a system able to address nanoparticles to the CNS [”
MethodA review of nanocarrier-based CNS delivery systems.
Tiwari, S. B., & Amiji, M. (2006) · Current Drug Delivery · doi:10.2174/156720106776359230 · Cited by 200 · cited 1× · see citing works
“The small size of the nanoparticles enables them to penetrate the BBB and facilitate delivery of drugs across the barrier. Nanoparticles for CNS Drug DeliveryThe use of nanoparticles to deliver drugs to the brain across the BBB may provide a significant advantage over current strategies. The primary advantage of nanop…”
BackgroundXie, Y., Ye, L., Zhang, X., Cui, W., Lou, J., Nagai, T., & Hou, X. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.03.005 · Cited by 168 · see citing works
Targeting liposomes with protein drugs to the blood–brain barrier in vitro
Visser, C. C., Stevanović, S., Voorwinden, L. H., van Bloois, L., Gaillard, P. J., Danhof, M., Crommelin, D. J. A., & de Boer, A. G. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.03.008 · Cited by 114 · see citing works
Role of nanotechnology in developing new therapies for diseases of the nervous system.
Jain, K. (2006) · Nanomedicine · doi:10.2217/17435889.1.1.9 · Cited by 55 · cited 1×
“ConclusionsAdvances in nanobiotechnology are being applied to improve the limitations of drug delivery to the CNS. Nanoparticle-based preparations can cross the BBB. There are potential toxic effects of nanoparticles on the brain and these issues need to be resolved prior to therapeutic use in CNS disorders. Although…”
BackgroundSelf-citation
Flagged first, then by citations
3 of the 15 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Nanomaterials for Neural Interfaces
Kotov, N. A., Winter, J. O., Clements, I. P., Jan, E., Timko, B. P., Campidelli, S., Pathak, S., Mazzatenta, A., Lieber, C. M., Prato, M., et al. (2009) · Advanced Materials · doi:10.1002/adma.200801984 · Cited by 504 · see citing works
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca‐Santos, B., Chorilli, M., & Gremião, M. P. D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 313 · see citing works
“Finally, a combination of the effects described above can be used (Figure 3).(158,160,163) NPs can also be administered nasally to promote absorption(169) and delivery to the brain.”
InfluentialNanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works
“As nanomedicines have to interact with neurons to show their response, multidimensional interaction at neuronal level and restricted anatomical access increase the challenges in nano-based drug delivery (Jain, 2007).”
BackgroundMethodPAMAM dendrimers as promising nanocarriers for RNAi therapeutics
Kesharwani, P., Banerjee, S., Gupta, U. D., Amin, M. C. I. M., Padhyé, S., Sarkar, F. H., & Iyer, A. K. (2015) · Materials Today · doi:10.1016/j.mattod.2015.06.003 · Cited by 290 · see citing works
Nanomedicine: Application of Nanobiotechnology in Medical Practice
Jain, K. (2008) · Medical Principles and Practice · doi:10.1159/000112961 · Cited by 247 · see citing works
“Use of nonintrusive, biocompatible and biodegradable nanoprobes improves our understanding of the brain at the neuron-to-neuron interaction level. Delivery of drugs to the central nervous system is a challenge and various strategies based on nanobiotechnology are discussed elsewhere [”
BackgroundSelf-citationNanobiotechnology-based strategies for crossing the blood-brain barrier.
Jain, K. (2012) · Nanomedicine · doi:10.2217/nnm.12.86 · Cited by 207 · see citing works
Self-citationNanoemulsions: increasing possibilities in drug delivery
Sutradhar, K. B., & Amin, M. L. (2013) · European Journal of Nanomedicine · doi:10.1515/ejnm-2013-0001 · Cited by 216 · see citing works
Recent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 212 · see citing works
Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke
Sifat, A. E., Vaidya, B., & Abbruscato, T. J. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0091-7 · Cited by 172 · see citing works
MicroRNA-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain
Zeng, L., He, X., Wang, Y., Tang, Y., Zheng, C., Cai, H., Liu, J., Wang, Y., Fu, Y., & Yang, G. (2013) · Gene Therapy · doi:10.1038/gt.2013.55 · Cited by 168 · see citing works
Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates
Mukhtar, M., Bilal, M., Rahdar, A., Barani, M., Arshad, R., Behl, T., Brisc, C., Bănică, F., & BUNGAU, S. G. (2020) · Chemosensors · doi:10.3390/chemosensors8040117 · Cited by 166 · see citing works
“It is of significance that therapeutic substances or drugs can be transported to the brain at substantially lower concentrations compared to the standard doses of free drugs, leading to safe drug administration to achieve therapeutic effectiveness [77].”
BackgroundNanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy
Zottel, A., Paska, A. V., & Jovčevska, I. (2019) · Materials · doi:10.3390/ma12101588 · Cited by 147 · see citing works
“This is of great importance, since, with targeted delivery systems, chemotherapeutic drugs like paclitaxel can be delivered to the brain in concentrations lower than standard therapeutic doses of the free drug, which results in safer drug dosing while still achieving desired therapeutic efficacy [14].”
BackgroundInfluentialFunctional Delivery of siRNA in Mice Using Dendriworms
Agrawal, A., Min, D., Singh, N., Zhu, H., Birjiniuk, A., von Maltzahn, G., Harris, T. J., Xing, D., Woolfenden, S. D., Sharp, P. A., et al. (2009) · ACS Nano · doi:10.1021/nn900201e · Cited by 147 · see citing works
Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)
Sela, H., Cohen, H., Elia, P., Zach, R., Karpas, Z., & Yehuda Zeiri, B. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0133-1 · Cited by 129 · see citing works
“The process should be controllable and safe, with no negative effect on BBB integrity, and it should be biocompatible and selective [4–8].”
BackgroundMethodTheranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging
Fang, J., Wen, C.-J., Zhang, Z., Al-Suwayeh, & Yen, T. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29369 · Cited by 126 · see citing works
“35 It could occur with theranostic liposomes since polyethylene glycol is recognized by low-density lipoprotein receptors on brain endothelial cells 36 Caveolae are invaginations on the cell membrane which are coated with caveolin.”
BackgroundCuring epilepsy: Progress and future directions
Jacobs, M. P., Leblanc, G. G., Brooks‐Kayal, A. R., Jensen, F. E., Lowenstein, D. H., Noebels, J. L., Spencer, D. D., & Swann, J. W. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2009.02.036 · Cited by 121 · see citing works
“Nanoparticles offer a new method for delivery into the brain of both gene therapy vectors and traditional pharmaceutical agents [141].”
Nanogels as novel drug nanocarriers for CNS drug delivery
Vasanthan, M., Nivetha, R. P., Tamilanban, T., Narayanan, J., Subramaniyan, V., Fuloria, N. K., Chinni, S. V., Sekar, M., Fuloria, S., Wong, L. S., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1232109 · Cited by 125 · see citing works
“Additionally, by including diagnostic chemicals into their architecture, nanogels can be used to simultaneously diagnose and treat CNS illnesses (Jain, 2007).”
BackgroundInfluentialZhao, Y., Lin, M., Lin, Q., Yang, W., Yu, X., Tian, F., Mao, K., Yang, J., Lu, C., & Wong, H. L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.017 · Cited by 109 · see citing works
Vlieghe, P., & Khrestchatisky, M. (2012) · Medicinal Research Reviews · doi:10.1002/med.21252 · Cited by 104 · see citing works
Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's
Nirale, P., Paul, A., & Yadav, K. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117394 · Cited by 103 · see citing works
Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective
Soni, S., Ruhela, R. K., & Medhi, B. (2016) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2016.044 · Cited by 100 · see citing works
Brain-Targeting Mechanisms of Lactoferrin-Modified DNA-Loaded Nanoparticles
Huang, R., Ke, W., Han, L., Liu, Y., Shao, K., Ye, L., Lou, J., Jiang, C., & Pei, Y. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.104 · Cited by 91 · see citing works
“Otherwise, NPs with different sizes were reported to penetrate the BBB through different mechanisms, such as receptor-mediated transcytosis (Bharali et al, 2005; Jain, 2007; Liu et al, 2008; Reimold et al, 2008).”
BackgroundJafari, Z., Bigham, A., Sadeghi, S., Dehdashti, S. M., Rabiee, N., Abedivash, A., Bagherzadeh, M., Nasseri, B., Karimi‐Maleh, H., Sharifi, E., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01144 · Cited by 85 · see citing works
Alotaibi, B. S., Buabeid, M. A., Ibrahim, N. A., Kharaba, Z. J., Ijaz, M., Noreen, S., & Murtaza, G. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s333657 · Cited by 83 · see citing works
“nature of BBBs to drug molecules efficiently targets drugs to the brain.(31) Low concentrations of pharmaceuticals,”
BackgroundMignani, S. M., Bryszewska, M. J., Zabłocka, M., Klajnert‐Maculewicz, B., Cladera, J., Shcharbin, D., & Majoral, J. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.09.006 · Cited by 77 · see citing works
Strategies for drug delivery to the central nervous system by systemic route
Kasinathan, N., Jagani, H., Alex, A. T., Subrahmanyam, V. M., & Rao, J. V. (2014) · Drug Delivery · doi:10.3109/10717544.2013.878858 · Cited by 67 · see citing works
“This further prevents the exit of the drugs from the brain (Jain, 2007).”
BackgroundDamage mechanism and therapy progress of the blood-brain barrier after ischemic stroke
Gao, H., Chen, H., Cui, G.-Y., & Hu, J.-X. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01126-z · Cited by 65 · see citing works
“Nanoparticles such as liposomes have been used for drug delivery, as they can minimize chemical degradation, improve drug permeability, and achieve the necessary blood drug concentration at the site of action [151–153].”
MethodRole of Nanobiotechnology in the Development of Personalized Medicine
Jain, K. (2009) · Nanomedicine · doi:10.2217/nnm.09.12 · Cited by 63 · see citing works
Self-citationRhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63 · see citing works
“In the future, nanoparticles and their complex mixture including therapeutic substances may be considered as an effective tool in brain medication delivery for the development of better medicines (Halberstadt et al., 2006; Jain, 2007; Singh et al., 2019a; Singh et al., 2019b).”
BackgroundMethodDelivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain
Lin, Y., Pan, Y., Shi, Y., Huang, X., Jia, N., & Jiang, J. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/16/165101 · Cited by 60 · see citing works
Nanobiotechnology-based Drug Delivery in Brain Targeting
Dinda, S. C., & Pattnaik, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140608143719 · Cited by 60 · see citing works
“com of the Nanomaterials used and its combination with therapeutic moieties, for example the use of liposomes and polymeric nanoparticles [2, 3].”
MethodPolymeric Nanocarriers: New Endeavors for the Optimization of the Technological Aspects of Drugs
Sosnik, A., Carcaboso, A. M., & Chiappetta, D. A. (2008) · Recent Patents on Biomedical Engineering · doi:10.2174/1874764710801010043 · Cited by 55 · see citing works
“Nanoencapsulation enhances the transfer across the main hurdle: the brain blood barrier (BBB) (for recent reviews read [36,37]).”
BackgroundNew insights into targeted therapy of glioblastoma using smart nanoparticles
Ghaznavi, H., Afzalipour, R., Khoei, S., Sargazi, S., Shirvalilou, S., & Sheervalilou, R. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03331-3 · Cited by 47 · see citing works
Nanotechnology in Spine Surgery: A Current Update and Critical Review of the Literature
Viswanathan, V. K., Manoharan, S. R. R., Subramanian, S., & Moon, A. S. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.11.035 · Cited by 44 · see citing works
BDNF increases homotypic olivocerebellar reinnervation and associated fine motor and cognitive skill
Willson, M. L., McElnea, C., Mariani, J., Lohof, A. M., & Sherrard, R. M. (2008) · Brain · doi:10.1093/brain/awn024 · Cited by 44 · see citing works
“A threshold of reinnervation, rapidly improving peptide delivery to the CNS (Jain, 2007; de Boer and Gaillard, 2007) and the efficacy of a single post-lesion, albeit invasive, treatment broadens our understanding of recovery from neural injury/dysfunction.”
BackgroundInfluentialNanomedicine for glioblastoma: Progress and future prospects
Khan, I., Baig, M. H., Mahfooz, S., Imran, M. A., Khan, M. I., Dong, J.-J., Choi, Y., & Hatiboğlu, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.007 · Cited by 43 · see citing works
Nanotechnology for the Treatment of Spinal Cord Injury
Zimmermann, R., Alves, Y. V., Sperling, L. E., & Pranke, P. H. L. (2020) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2020.0188 · Cited by 38 · see citing works
“80 Different materials can be used to synthesize nanoparticles, such as polymers, metals, metal oxides, and biological molecules.”
Bodunde, O. P., Ikumapayi, O. M., Akinlabi, E. T., et al. (2020) · Materials Today Proceedings · doi:10.1016/j.matpr.2020.11.232 · Cited by 39 · see citing works
Koopmans, R. J., & Aggeli, A. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.01.012 · Cited by 37 · see citing works
“Several systems are developed targeted at cardio-vascular diseases [15–17], others aim at gene therapies [17,18], and some aim at selectively targeting tumour cells or diseases associated with the nerve system [19–22].”
BackgroundAntidepressant and cognitive activities of intranasal piperine-encapsulated liposomes
Priprem, A., Chonpathompikunlert, P., Sutthiparinyanont, S., & Wattanathorn, J. (2011) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2011.22017 · Cited by 33 · see citing works
“a compound is given in liposomal forms is expected [15,29], thus, for piperine, a lower dose was estimated and proposed for the first time in this study.”
BackgroundYuan, S., Ma, T., Zhang, Y., Wang, N., Baloch, Z., & Ma, K. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02159-9 · Cited by 32 · see citing works
Nakhjavani, M., Samarasinghe, R. M., & Shigdar, S. L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.010 · Cited by 31 · see citing works
Nanomedicine in Targeted Drug Delivery: Precision Therapeutics for Personalized Medicine
Dey, S., Hassan, S., & Pandey, R. K. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_8 · Cited by 32 · see citing works
Guerrab, W., Jemli, M. E., Akachar, J., et al. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1922096 · Cited by 28 · see citing works
“It acts as anatomical and biochemical dynamic barrier in the brain (Dominguez et al., 2014; Jain, 2007; Wong et al., 2012).”
BackgroundDas, M. K., Sarma, A., & Chakraborty, T. (2016) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0293-z · Cited by 29 · see citing works
“They can be transported across the BBB without any damage to the BBB [43].”
BackgroundMhambi, S., Fisher, D. W., Tchokonte, M. B. T., & Dube, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091479 · Cited by 24 · see citing works
“The absorption of polar drugs can be achieved by increasing their hydrophobicity, however, the volume of distribution of the drug within the body will also increase [53,65].”
BackgroundWen, C.-J., Yen, T., Al‐Suwayeh, S. A., et al. (2011) · Nanomedicine · doi:10.2217/nnm.11.46 · Cited by 25 · see citing works
Zhao, Y., Zhao, W., Yu, S., et al. (2013) · Bio-Medical Materials and Engineering · doi:10.3233/bme-130775 · Cited by 22 · see citing works
“Of which electrospun fibrous matrices have a high surface-area-to-volume ratio suitable for cell attachment and growth as well as a possibility of mimicking the ECM architecture favorable to tissue regeneration [6,7].”
Tomanin, R., Zanetti, A., Zaccariotto, E., D'Avanzo, F., Bellettato, C. M., & Scarpa, M. (2012) · Acta paediatrica · doi:10.1111/j.1651-2227.2012.02674.x · Cited by 24 · see citing works
“The primary advantage of nanomaterial carriers is that they mask the features of the carried gene, as size and polarity, thus also containing a possible immuno-response, all these causes limiting BBB crossing efficiency (57).”
BackgroundTargeting ischemic penumbra Part II: selective drug delivery using liposome technologies
Liu, S., Levine, S. R., & Winn, H. R. (2011) · Journal of Experimental Stroke and Translational Medicine · doi:10.6030/1939-067x-4.1.16 · Cited by 22 · see citing works
“(Jain 2007; Tiwari and Amiji 2006) J Exp Stroke Transl Med.”
BackgroundMiR-137–3p rescue motoneuron death by targeting calpain-2
Tang, Y., Fu, R., Ling, Z., Liu, L., Yu, G., Li, W., Fang, X.-Y., Zhu, Z., Wu, W.-T., & Zhou, L. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.01.008 · Cited by 24 · see citing works
Zucca, G., Vigani, B., Valentino, C., Ruggeri, M., Marchesi, N., Pascale, A., Giovilli, G., Malavasi, L., Sandri, G., & Rossi, S. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s488507 · Cited by 20 · see citing works
Nanotechnological Advancements in the Brain Tumor Therapy: a Novel Approach
Angolkar, M., Paramshetti, S., Halagali, P., Jain, V. K., Patil, A. B., & Somanna, P. (2022) · Therapeutic Delivery · doi:10.4155/tde-2022-0035 · Cited by 20 · see citing works
Nanotechnology-enabled therapies improve blood-brain barrier challenges in brain tumor
Wenqi, Y., Lingxi, W., Mehmood, A., & Shah, W. (2023) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2291105 · Cited by 18 · see citing works
“By understanding these aspects, researchers developed techniques that enhance the transport of therapeutic agents across the BBB without the need for invasive procedures [19, 28–31] .”
InfluentialNanoemulsions Challenges and Future Prospects as a Drug Delivery System
Abaszadeh, F., Ashoub, M. H., & Amiri, M. (2023) · Smart nanomaterials technology · doi:10.1007/978-981-99-5398-1_13 · Cited by 19 · see citing works
PAMAM-drug complex for delivering anticancer drug across blood-brain barrier in-vitro and in-vivo
Cui, D., Xu, Q., Gu, S., et al. (2009) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp.9000212 · Cited by 17 · see citing works
PROGRESS and FUTURE DIRECTIONS
Poland, T. M. (2014) · Cited by 13 · see citing works
Jha, S. K., Imran, M., Paudel, K. R., et al. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0444 · Cited by 11 · see citing works
Chauhan, M., Singh, R. P., Sonali, Yadav, B., Shekhar, S., Kumar, L., Mehata, A. K., Jhawat, V., Dutt, R., Garg, V., et al. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113544 · Cited by 10 · see citing works
Jiang, W., Badehnoosh, B., & Ruan, W. (2025) · npj Science of Food · doi:10.1038/s41538-025-00653-y · Cited by 12 · see citing works
Nanotechnology, Nanostructure, and Nervous System Disorders
Woolf, N. J., Priel, A., & Tuszyński, J. A. (2009) · Biological and medical physics series · doi:10.1007/978-3-642-03584-5_5 · Cited by 8 · see citing works
Mozafari, M. (2014) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2013.0053 · Cited by 9 · see citing works
Nanoneurology - Drug Delivery across the Brain Protective Barriers
Fymat, A. L. (2017) · Journal of Nanomedicine Research · doi:10.15406/jnmr.2017.05.00105 · Cited by 8 · see citing works
Nanotechnology-Enhanced Orthopaedic Surgery
Pang, A. S., Liau, Z. Q. G., Oh, J. Y.-L., & Srinivasan, D. K. (2024) · Journal of Nanotheranostics · doi:10.3390/jnt5040011 · Cited by 9 · see citing works
“This technology, which builds up increasingly complex structures from atomic-sized particles instead of breaking complex materials down into smaller ones, has the potential to deliver medications or other components [10]. ones, has the potential to deliver medications or other components [10].”
Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases
Nguyen‐Thi, P., Ho, T.-T., Nguyen, T. T., & Vo, G. V. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230707113405 · Cited by 8 · see citing works
Occupational medicine implications of engineered nanoscale particulate matter
Kelly, R. J. (2008) · ACS Chemical Health & Safety · doi:10.1016/j.jchas.2008.03.012 · Cited by 8 · see citing works
Nagaraju, P. G., Ashwini, S., & G., P. P. C. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2092446 · Cited by 7 · see citing works
“They will cross the BBB through a technique explained by an increased retention mechanism with the absorption of the NPs to the capillary walls (Jain 2007); these events depend on the concentration gradient.”
BackgroundMethodPark, S., Kim, Y.-K., Youn, H., et al. (2008) · Molecular & Cellular Toxicology · Cited by 7 · see citing works
Metal Nanoparticles in Management of Diseases of the Central Nervous System
Ingle, A. P., SHENDE, S. S., Gupta, I. R., Nagaonkar, D., Pandit, R., Paralikar, P., & Rai, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813806-9.00005-6 · Cited by 9 · see citing works
Evaluation the toxic effects of Cobalt-Zinc Ferrite nanoparticles in experimental mice
El‐Nahass, E., Salem, B. I., El-Naggar, S. A., & Elwan, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-90043-x · Cited by 8 · see citing works
“Prior research has shown the utilization of Au and Ag nanoparticles in the therapy of cancer 33,34 ).”
Polymer Gels Made with Functionalized Organo-Silica Nanomaterials for Conformance Control
Najafiazar, B., Wessel‐Berg, D., Bergmo, P. E. S., et al. (2019) · Energies · doi:10.3390/en12193758 · Cited by 6 · see citing works
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
Prakash, S. (2009) · Biologics · doi:10.2147/btt.s4672 · Cited by 6 · see citing works
“Nanotechnology could also be used for the targeted gene delivery.(108) Research is in progress to use this technology to transfer the gene or drug at particular site which is otherwise impossible in clinical studies.”
Nano Chemotherapy: An Emergent Anti-Cancer Modality
Fymat, A. L. (2017) · Global Journal of Nanomedicine · doi:10.19080/gjn.2017.01.555555 · Cited by 5 · see citing works
“Abbreviations: BBB: Blood Brain Barrier; BVP: Bleomycin + Vinblastine + Cisplatin; CNS: Central Nervous System; CNT: Carbon Nano Tubes; CSC: Cancer Stem Cells; CUR: Curcumin; DDP: Cisplatin; Docetaxel; DOX: Doxorubicin; DTX: Docetaxel; END: Engineered Nanoscale Device; FDA: (U.S.) Food and Drug Administration; IR: Inf…”
BackgroundNawaz, N., Arshad, M., Mehmood, N., Hassan, W., Shah, S. Z. H., & Siddique, F. (2020) · Indian Journal of Fisheries · doi:10.21077/ijf.2019.67.2.84748-11 · Cited by 5 · see citing works
Terapia génica en el tratamiento de los errores congénitos del metabolismo
Pérez‐López, J. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.030 · Cited by 5 · see citing works
Chitosan nanoparticles modified by polyethylene glycol as lamivudine drug delivery system
Astuti, S., Yulizar, Y., Saefumillah, A., et al. (2020) · AIP conference proceedings · doi:10.1063/5.0007925 · Cited by 5 · see citing works
Nanooncology: Perspective on Promising Anti-Tumor Therapies
Fymat, A. L. (2017) · Journal of Tumor Medicine & Prevention · doi:10.19080/jtmp.2017.01.555555 · Cited by 5 · see citing works
“d) Can be packed with many small drug molecules that diffuse out of the polymer core and through the platelet membrane onto their targets [35-37].”
BackgroundLipid nanoparticles in targeting Alzheimer's disease
Kendre, P. N., Pote, A. K., Bhalke, R. D., Prajapati, B. G., Jain, S. P., & Kapoor, D. U. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00021-2 · Cited by 4 · see citing works
How does “Protein Corona” Affect the In vivo Efficiency of Polymeric Nanoparticles? State of Art
(2017) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681084930117020011 · Cited by 3 · see citing works
Recent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders
Marei, H. E. S. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01703-z · Cited by 2 · see citing works
“In addition, to enhance permeability across the blood-brain barrier and to promote targeting to the appropriate cell type, many researchers have developed “non-viral” vectors that contain targeting ligands or cytoplasmic delivery peptides, enabling targeted delivery and transfection (Jain 2007).”
Zayed, G. (2010) · University of Regensburg Publication Server (University of Regensburg) · Cited by 2 · see citing works
Nanotechnology in Iron Deficiency Anemia: A review
Iyer, S., & Chand, D. (2020) · International Conference on Reliability, Infocom Technologies and Optimization (Trends and Future Directions) (ICRITO) · doi:10.1109/icrito48877.2020.9197850 · Cited by 1 · see citing works
Presswala, Z., Acharya, S. P., & Shah, S. (2024) · ADMET & DMPK · doi:10.5599/admet.2214 · Cited by 1 · see citing works
“Hydrophilic or lipophilic neuropharmaceutical substances can be loaded into nanoscopic formulations of biodegradable/ Biocom-patible/ synthetic/ natural polymers in solid or solution form, protecting them against biological and chemical risks [54].”
BackgroundTyagi, S., Kumar, J., & Kumar, S. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2580488 · Cited by 1 · see citing works
Targeting ischemic penumbra Part II: selective drug delivery using liposome technologies
Liu, S., Levine, S. R., & Winn, H. R. (2011) · Journal of Experimental Stroke and Translational Medicine · doi:10.4172/1939-067x.1000134 · Cited by 1 · see citing works
Keyhanvar, P., Rezaei, M. H., Hazrati, H., Hazratgholizad, S., & Bakhshayesh, A. S. (2024) · Depiction of Health · doi:10.34172/doh.2024.17 · Cited by 1 · see citing works
Nanomaterials in Brain Cancer Management with Special Emphasis on Personalized Therapy
De, S., & Kirtania, M. D. (2024) · Current Nanomedicine · doi:10.2174/0124681873325767240902114719 · Cited by 1 · see citing works
Evaluation the toxic effects of Cobalt/Zinc/Ferrite nano-complex in experimental micePreprint
El‐Nahass, E., El-Naggar, S. A., Salem, B. I., & Elwan, M. (2021) · Research Square · doi:10.21203/rs.3.rs-941124/v1 · Cited by 1 · see citing works
Application of Nanophytomedicine for the Treatment of Central Nervous System Disorders
Rarokar, N. R., Gurav, N. S., & Gurav, S. S. (2023) · doi:10.1002/9781119794127.ch18 · Cited by 1 · see citing works
Nanowire Interfaces to Cells and Tissue
Zhang, A., Zheng, G., & Lieber, C. M. (2016) · Nanoscience and technology · doi:10.1007/978-3-319-41981-7_11
Wang, Y. (2014) · TSpace (University of Toronto)
Blood-Brain Barrier–Targeted Nanotechnological Advances
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00005-7
Significance of nanosomes for diagnosis of Alzheimer’s disease
Raja, N., Karuppiah, H., & Easwaran, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821013-0.00010-6
การพฒนาอนภาคทรงกลมขนาดไมครอนสำหรบนำสงสารสกดชาเขยวเพอรกษาโรคขอเสอม
ลิขิตเดชาโรจน์, ป. (2017) · doi:10.58837/chula.the.2017.1382
Nanomedicines in the Treatment of Nervous System Disorders
Zeb, Z., Sharif, A., Abdel‐Daim, M. M., Anjum, S. M. M., Khalil, A. A. K., Akhtar, M. F., Saleem, A., & Khan, M. I. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_5
Rana, B., & Dhiman, S. (2024) · AIP conference proceedings · doi:10.1063/5.0228762
Next-Generation Multifunctional Nanocarriers: A Comprehensive Review
Vihal, S., Rana, R., SINGH, V. A., Kaushik, M., & Gandhi, H. (2025) · Current Nanomedicine · doi:10.2174/0124681873353824250603105136
Advancements in Brain Tumor Treatment: Harnessing Nanotechnology for Promising Solutions
Patel, D. J., Patel, V., & Patel, U. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811747125010007
Utilizing nanotechnology to diagnose and treat central nervous system disorders
Shahabinejad, E., Shakoeizadeh, A., Karimabad, M. N., Asadi, F., Heydari, M., & Rabori, M. S. (2026) · Neurological Sciences · doi:10.1007/s10072-025-08750-2
- Authors
- Jain, K. K.
- Affiliations
- Jain PharmaBiotech (Switzerland) (CH)
- Corresponding author
- Jain, K.K.
- Venue
- Neurodegenerative Diseases
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 4
- Issue
- 4
- Pages
- 287-291
- ISSN
- 1660-2854 (ISSN-L)
- 1660-2862
- OpenAlex
- W17627131
- Cited by
- 100
- References
- 15
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 8 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 5
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- green
- id.nii.ac.jp
- Licence
- Locations
- Neurodegenerative Diseases (publishedVersion)
- PubMed (publishedVersion)
- Rikkyo University academic repository (Rikko Roots) (Rikkyo University) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- 立教経済学研究
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanobiotechnology, brain drug delivery, blood-brain barrier, nanoparticles, liposomes, polymeric nanoparticles, nanofluidic channels, nanoparticle safety, central nervous system disorders
- MeSH terms
- Animals, Blood-Brain Barrier, Central Nervous System, Central Nervous System Agents, Humans, Drug Delivery Systems, Nanotechnology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
